6 completed. 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
Follow IFX-1: new trials by email Literature Review of IFX-1 trials Research Report on IFX-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum vilobelimab - Pyoderma Gangrenosum | Phase 2 | Completed | InflaRx GmbH | 19 | 2019-05-16 | 2023-09-14 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) IFX-1, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Completed | InflaRx GmbH | 179 | 2018-02-26 | 2021-04-08 |
| Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa IFX-1 - Hidradenitis Suppurativa | Phase 2 | Completed | InflaRx GmbH | 12 | 2016-12-01 | 2017-09-19 |
| Studying Complement Inhibition in Complex Cardiac Surgery IFX-1, Placebo - Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac | Phase 2 | Completed | InflaRx GmbH | 116 | 2016-05-01 | 2017-02-15 |
| Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction CaCP29, Placebo - Severe Sepsis, Septic Shock | Phase 2 | Completed | InflaRx GmbH | 72 | 2014-04-01 | 2016-04-25 |
Hidradenitis Suppurativa (2) · Inflammation (2) · Systemic Inflammatory Response Syndrome (2) · Granulomatosis with Polyangiitis (1) · Microscopic Polyangiitis (1) · Pathologic Processes (1) · Pyoderma Gangrenosum (1) · Sepsis (1) · Shock, Septic (1) · Skin Diseases (1) · Systemic Vasculitis (1)
InflaRx GmbH (6)
Germany (4) · Canada (2) · France (2) · Greece (2) · Netherlands (2) · Poland (2) · United States (2) · Belgium (1) · Bulgaria (1) · Czechia (1) · Denmark (1) · Italy (1) · Russia (1) · Spain (1) · Sweden (1)
Anja Pfaff, PhD (1) · Michael Bauer, Prof. Dr. (1) · Othmar Zenker, CMO (1) · Peter A. Merkel, MD, MPH (1) · Prof. Niels C. Riedemann, M.D., Ph.D. (1) · Torsten Doenst, Prof. Dr. (1)
2015 (1)